According to cross-sectional and longitudinal studies YKL-40 possesses a good potential as a reliable biomarker of neuroinflammation in AD, because its levels are increased in preclinical AD [92] and linked to biomarkers of neurodegeneration (total tau, t-tau), tau-mediated toxicity (p-tau) [89]. The gene discussed is MAPT; the disease is Alzheimer disease.